Onset Therapeutics Announces Release of Study Results Demonstrating That ANESTAFOAM(R) (Lidocaine 4% Foam) Reduces Pain Associated with Common Dermatologic Procedures

CUMBERLAND, R.I.--(BUSINESS WIRE)--Results from an open label study assessing the reduction in Procedure-Associated Pain with the use of a lidocaine 4% foam (ANESTAFOAM® ) were published in the April issue of The Journal of Clinical and Aesthetic Dermatology. Evidence from this study suggests that ANESTAFOAM® (indicated for the relief of pain associated with minor cuts, burns, abrasions, sunburn, and insect bites) may be acceptable to patients and clinicians for the safe and effective reduction of pain associated with cosmetic dermatologic laser procedures.